SCHEMBL1655144

SCHEMBL1655144

O=C1/C(=C/c2ccco2)SC(=S)N1CCc1ccccc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 15/20 0.78
▸ KMT2A Q03164 15/20 0.78
▸ POLB P06746 14/20 0.78
▸ MAPT P10636 13/20 0.78
▸ ALDH1A1 P00352 8/20 0.78
▸ RECQL P46063 7/20 0.78
▸ TDP1 Q9NUW8 6/20 0.78
▸ LMNA P02545 4/20 0.78
▸ SMN1; SMN2 Q16637 2/20 0.78
▸ ALOX12 P18054 2/20 0.78
▸ L3MBTL1 Q9Y468 8/20 0.70
▸ MAPK1 P28482 6/20 0.70
▸ USP2 O75604 4/20 0.70
▸ KDM4E B2RXH2 6/20 0.69
▸ APEX1 P27695 5/20 0.69
▸ FFAR1 O14842 1/20 0.69
▸ HTT P42858 1/20 0.63
▸ NPC1 O15118 2/20 0.61
▸ RAB9A P51151 1/20 0.61
▸ THRB P10828 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1655147 1.00 MEN1 (0.78) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL1655145 1.00 MEN1 (0.78) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL3971529 0.83 KMT2A (0.87) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL3971531 0.83 KMT2A (0.87) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL3893459 0.81 MAPT (1.00) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL3893463 0.81 MAPT (1.00) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL3131569 0.81 KMT2A (0.71) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL3131576 0.81 KMT2A (0.71) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL3131559 0.81 KMT2A (0.71) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL10492218 0.81 POLB (0.75) MEN1KMT2APOLBMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US claimed
WO-2005041951-A2 RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2005-05-12 — — WO claimed
US-20120202814-A1 COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF UNIVERSITÀ DEGLI STUDI DI SIENA (IT) 2012-08-09 — — US disclosed
WO-2011039735-A2 COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF CONSIGLIO NAZIONALE DELLE RICERCHE (IT) 2011-04-07 — — WO disclosed
US-7566732-B2 Rhodanine compositions for use as antiviral agents RIGEL PHARMACEUTICALS, INC. (US) 2009-07-28 — — US disclosed
US-7566732-B2 Rhodanine compositions for use as antiviral agents RIGEL PHARMACEUTICALS, INC. (US) 2009-07-28 — — US disclosed
US-7566732-B2 Rhodanine compositions for use as antiviral agents RIGEL PHARMACEUTICALS, INC. (US) 2009-07-28 — — US disclosed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US disclosed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US disclosed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US disclosed
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them RIGEL PHARMACEUTICALS, INC. (US) 2006-12-07 — — US disclosed
WO-2005041951-A2 RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2005-05-12 — — WO disclosed
WO-2004043955-A1 RHODANINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM RIGEL PHARMACEUTICALS, INC. (US) 2004-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202814-A1 COMPOUNDS WITH DDX3 INHIBITORY ACTIVITY AND USES THEREOF DDX3X, DDX21, DDX39B MEN1 1855/4885KMT2A 2610/4885POLB 658/4885
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them UBQLN1, UBQLN2, UBE2G2 MEN1 1562/4885KMT2A 901/4885POLB 2008/4885
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RBX1, ITCH, UBQLN1 MEN1 2869/4885KMT2A 1020/4885POLB 433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback